FindTrial
Sign In

MELODy versus CHOPL in de novo peripheral T cell lymphoma: a prospective randomized controlled clinical study

MELODy versus CHOPL in de novo peripheral T cell lymphoma: a prospective randomized controlled clinical study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPC-15006962
Enrollment
Unknown
Registered
2015-08-22
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non Hodgin Lymphoma

Interventions

group A:MELODy regimen

Sponsors

Changhai Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. de novo, peripheral T cell lymphoma confirmed by pathologist; 2. Both gender, aged 18-70 year-old; 3. Bone marrow functioned well; 4. Renal function normal; 5. Liver function normal; 6. patients are voluntary, and willing to sign informed consent; 7. expected lifetime was at least more than 6 months.

Exclusion criteria

Exclusion criteria: 1. Patients with ejection fraction =2.

Design outcomes

Primary

MeasureTime frame
complete remission rate;—

Secondary

MeasureTime frame
overall remission rate;overall survival;progression free survival;—

Countries

China

Contacts

Public ContactJianmin Yang
yangjianmin@csco.org.cn+86 021-31161282

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026